10% chegirma bering
Maslahat bering ushbu kitobni do'stingiz sotib olganidan 298 265,95 soʻm oling.
0+
matnPDF
Hajm 552 sahifalar
Apicomplexan Parasites. Molecular Approaches toward Targeted Drug Development
matnPDF
2 982 659,46 soʻm
Kitob haqida
This handbook is the first dealing with the discovery of drugs directed against apicomplexan parasites. Amongst others, this group of endoparasites includes the causative agents of Malaria, Toxoplasmosis, and Babesiosis, the latter occurring mainly in animals. Written by renowned scientific experts from academia and industry, the book focuses on currentdrug development approaches for all apicomplexan diseases making it appealing to a large audience, ranging from research labs in academia to the human and veterinarian pharmaceutical industry. This work is the second volume of the new book series 'Drug Discovery in Infectious Diseases', edited by Prof. Dr Paul M. Selzer.
Janrlar va teglar
Izoh qoldiring
Kirish, kitobni baholash va sharh qoldirish
Kitob tavsifi
This handbook is the first dealing with the discovery of drugs directed against apicomplexan parasites. Amongst others, this group of endoparasites includes the causative agents of Malaria, Toxoplasmosis, and Babesiosis, the latter occurring mainly in animals. Written by renowned scientific experts from academia and industry, the book focuses on currentdrug development approaches for all apicomplexan diseases making it appealing to a large audience, ranging from research labs in academia to the human and veterinarian pharmaceutical industry. This work is the second volume of the new book series 'Drug Discovery in Infectious Diseases', edited by Prof. Dr Paul M. Selzer.
Kitob «Apicomplexan Parasites. Molecular Approaches toward Targeted Drug Development» — veb-saytda onlayn o'qing. Fikr va sharhlar qoldiring, sevimlilarga ovoz bering.
Yosh cheklamasi:
0+Litresda chiqarilgan sana:
04 iyun 2018Hajm:
552 Sahifa ISBN:
9783527633890Umumiy o'lcham:
7.5 МБUmumiy sahifalar soni :
552Mualliflik huquqi egasi:
John Wiley & Sons Limited
